Hyloris Pharmaceuticals (XBRU:HYL) FCF Margin % : -549.21% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Hyloris Pharmaceuticals's Free Cash Flow for the six months ended in Dec. 2023 was €-9.08 Mil. Hyloris Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was €1.65 Mil. Therefore, Hyloris Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was -549.21%.

As of today, Hyloris Pharmaceuticals's current FCF Yield % is -4.11%.

The historical rank and industry rank for Hyloris Pharmaceuticals's FCF Margin % or its related term are showing as below:

XBRU:HYL' s FCF Margin % Range Over the Past 10 Years
Min: -6364.84 Med: -2073.24 Max: -397.64
Current: -477.93

During the past 8 years, the highest FCF Margin % of Hyloris Pharmaceuticals was -397.64%. The lowest was -6364.84%. And the median was -2073.24%.

XBRU:HYL's FCF Margin % is ranked worse than
66.51% of 1036 companies
in the Biotechnology industry
Industry Median: -148.935 vs XBRU:HYL: -477.93

Hyloris Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Hyloris Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals FCF Margin % Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-6,364.84

-2,967.43

-397.64

-470.79

-477.93

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial							-127.33	-640.17	-379.56	-376.29	-549.21

Competitive Comparison of Hyloris Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Hyloris Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's FCF Margin % falls into.

Hyloris Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Hyloris Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-13.449	/	2.814
	=	-477.93 %

Hyloris Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-9.084	/	1.654
	=	-549.21 %

Hyloris Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.